KEAL (sucralfate), medicinal product for the treatment of peptic ulcers

Insufficient actual benefit in the treatment of gastric and duodenal ulcers, in view of the more effective treatment alternatives

• KEAL has Marketing Authorisation in the treatment of progressive gastric and duodenal ulcers and in the maintenance therapy of duodenal ulcers in patients who are not infected with Helicobacter pylori or in whom its eradication has not been possible.
• It is a gastric coating. It does not have an antisecretory or an antacid action. Its efficacy/adverse effects ratio in the treatment of progressive gastroduodenal ulcers is low.
• Its role in the therapeutic strategy has become marginal, because of the existence of more effective treatment alternatives in the indications of the Marketing Authorisation.